A NOVEL ROLE OF SIRT1 IN SILDENAFIL INDUCED 
CARDIOPROTECTION IN MICE by Shalwala, Mona
Virginia Commonwealth University
VCU Scholars Compass
Theses and Dissertations Graduate School
2010
A NOVEL ROLE OF SIRT1 IN SILDENAFIL
INDUCED CARDIOPROTECTION IN MICE
Mona Shalwala
Virginia Commonwealth University
Follow this and additional works at: http://scholarscompass.vcu.edu/etd
Part of the Biochemistry, Biophysics, and Structural Biology Commons
© The Author
This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses
and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.
Downloaded from
http://scholarscompass.vcu.edu/etd/2170
ii 
 
 
 
 
COPYRIGHT PAGE 
 
 
 
 
 
 
 
 
© Mona Bipin Shalwala 2010 
All Rights Reserved 
 
iii 
A NOVEL ROLE OF SIRT1 IN SILDENAFIL INDUCED  
CARDIOPROTECTION IN MICE  
 
 
A thesis submitted in partial fulfillment of the requirements for the degree of Master of 
Science in Biochemistry at Virginia Commonwealth University. 
 
by 
 
MONA BIPIN SHALWALA 
The University of Pennsylvania, B.S.E. Bioengineering, 2007 
 
 
Director: DR. RAKESH C. KUKREJA, PH.D. 
SCHOOL OF MEDICINE 
DIVISION OF CARDIOLOGY 
 
 
 
 
 
 
 
Virginia Commonwealth University 
Richmond, Virginia 
May, 2010 
iv 
Acknowledgements 
I would like to express my sincere gratitude to the following people who have 
made my research experience both rewarding and productive.   
First and foremost, I would like to thank Dr. Rakesh Kukreja for serving as my 
primary investigator and research advisor.  I also appreciate the efforts of my committee 
members Dr. Frank Fang and Dr. Gea-Ny Tseng.  I would also like to thank Dr. Fadi 
Salloum and Dr. Shu Zhu for their assistance with surgical procedures.  I would also like 
to thank Dr. Rakesh Kukreja, Dr. Fadi Salloum, Dr. Lei Xi, and Dr. Anindita Das for 
spending countless hours teaching me experimental procedures, answering my questions, 
and imparting their knowledge.  Additionally, I thank Dr. Fadi Salloum, Dr. Lei Xi, Dr. 
Saisudha Koka, and Nick Hoke for teaching me and assisting me with animal procedures.  
Dr. Anindita Das must be thanked for teaching me biochemistry procedures.    
Thank you to the following lab members Dr. Ramzi Ockaili, Dr. Antonio Abbate, 
Dr. Amit Varma, Dr. Chang, Daniel Hobbs, James Rao, Vinh Chau, David Durrant, Eric 
Mayton, Sarah Hassanieh, and Shivani Desai for offering assistance and support 
throughout my project.   
Last but not least, I would like to thank my family for their continued support and 
love which allowed me to pursue a Master’s degree in Biochemistry.   
 
v 
Table of Contents 
Page 
Acknowledgements ............................................................................................................ iv 
List of Tables ................................................................................................................... viii 
List of Figures .................................................................................................................... ix 
List of Abbreviations ...........................................................................................................x 
Abstract .............................................................................................................................. xi 
Chapter 
1 Introduction ........................................................................................................1 
1.1 Cardiovascular Disease ...........................................................................1 
1.2 Ischemic and Pharmacological Preconditioning .....................................2 
1.3 SIRT1 ......................................................................................................4 
1.4 Activator and Inhibitor of SIRT1 ............................................................5 
1.5 SIRT1 and Cellular Stress Response .......................................................5 
1.6 PGC-1α and Myocardial I-R Injury ........................................................7 
1.7 SIRT1 and Heat Shock Response ............................................................8 
1.8 Rationale for the Present Study .............................................................10 
2 Materials and Methods .....................................................................................11 
2.1 Animals .................................................................................................11 
2.2 Antibodies and Chemicals .....................................................................11 
2.3 Drugs Preparation ..................................................................................12 
vi 
2.4 Myocardial infarction protocol ..............................................................12 
2.5 Measurement of Infarct Size and Risk Area .........................................17 
2.6 Assessment of Heart Function ...............................................................19 
2.7 Healthy Heart Harvestation ...................................................................19 
2.8 Isolation of Ventricular Cardiomyocytes ..............................................22 
2.9 Western blot analysis .............................................................................23 
2.10 Protein purification of SIRT1 for deacetylase activity analysis ..........24 
2.11 SIRT1 deacetylase activity assay ........................................................25 
2.12 Data analysis and statistics ..................................................................26 
3 Results ..............................................................................................................27 
3.1 Exclusions .............................................................................................27 
3.2 Sildenafil and Resveratrol preconditioning reduced infarct size ...........27 
3.3 Sirtinol blocked the preconditioning effect of Sildenafil and 
Resveratrol…………………………………………………………….31 
3.4 Sildenafil increased SIRT1 activity in vivo and in vitro .......................31 
3.5 Cardiovascular function ........................................................................37 
3.6 Western blot analysis .............................................................................40 
4 Discussion ........................................................................................................43 
4.1 Rationale of the Present study ...............................................................43 
vii 
4.2 SIRT1 is a key factor involved in the cardioprotective mechanism of 
Sildenafil following I-R injury ..............................................................44 
4.3 Sildenafil increases SIRT1 activity in vivo and in vitro .......................44 
4.4 Cardiac function studies ........................................................................45 
4.5 Sildenafil increased expression of common factors modulated by 
SIRT1 ....................................................................................................45 
4.6 Study Limitations ..................................................................................46 
4.7 Future Directions ...................................................................................47 
4.8 Clinical Implications .............................................................................48 
5 Literature Cited ................................................................................................49 
6 Vita ...................................................................................................................56 
viii 
List of Tables 
Page 
Table 1: Cardiovascular Function: Doppler Echocardiography Results. ...........................38 
Table 2: Cardiovascular Function: Doppler Echocardiography Results. ...........................39 
ix 
List of Figures 
Page 
Figure 1: Expermental Protocol 1 ......................................................................................14 
Figure 2: Experimental Protocol 2 .....................................................................................16 
Figure 3: Representative section of mouse heart ...............................................................18 
Figure 4: Experimental Protocol 3 .....................................................................................21 
Figure 5: A. Myocardial Infarct size. .................................................................................29 
Figure 5: B. Myocardial Risk area .....................................................................................30 
Figure 6: SIRT1 Activity after 24 hours of Pre-Treatment ................................................33 
Figure 7: SIRT1 Activity after 7 days of Pre-Treatment ...................................................34 
Figure 8: SIRT1 Activity after 24 hours Pre-Treatment and I-R .......................................35 
Figure 9: SIRT1 Activity in Cardiac Myocytes after 1hr Pre-Treatment ..........................36 
Figure 10: Cardiac expression of eNOS, SIRT1, and HSP70............................................41 
Figure 11: Cardiac expression of iNOS, PGC-1α, and HSP70 ..........................................42 
 
 
 
 
 
 
 
x 
List of Abbreviations 
 
AMI  Acute Myocardial Ischemia 
A.U.  Arbitrary units 
AWDT Anterior wall diastolic thickness 
AWST  Anterior wall systolic thickness 
cGMP  Cyclic guanine monophosphate 
DMSO  Dimethyl sulfoxide 
EF  Ejection fraction 
eNOS  Endothelial nitric oxide synthase 
FS  Fractional shortening 
GC  Guanylyl cyclase 
H  Hour  
HDAC  Histone deacytylase 
HR  Heart rate 
HSF  Heat shock factor 
HSP  Heat shock protein  
HSR  Heat shock response 
I-R  Ischemia-Reperfusion 
IP  Ischemic Preconditioning  
ip  Intraperitoneal 
iNOS  Inducible nitric oxide synthase 
LAD  Left anterior decending coronary artery 
LV  Left ventricle 
LVEDD Left ventricular end-diastolic diameter 
LVESD Left ventricular end-systolic diameter 
Min  Minutes 
NAD  Nicotinamide adnenine dinucleotide 
NO  Nitric oxide 
PBS  Phosphate buffered saline 
PDE-5  Phosphodiesterase 5 
PGC-1α Peroxisome proliferation activating receptor-gamma-co-activator-1-alpha 
PKG  Protein kinase G 
PWDT  Posterior wall diastolic thickness 
PWST  Posterior wall systolic thickness 
ROS  Reactive oxygen species 
RSV  Resveratrol 
SIL  Sildenafil  
TSA  Trichostatin A 
TTC  2, 3, 5-triphenyl tetrazolium chloride
xi 
 
 
 
 
ABSTRACT 
 
 
 
A NOVEL ROLE OF SIRT1 IN SILDENAFIL INDUCED  
CARDIOPROTECTION IN MICE  
 
By Mona B. Shalwala, B.S.E.  
A thesis submitted in partial fulfillment of the requirements for the degree of Masters of 
Science at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2010 
 
Major Director:  Dr. Rakesh Kukreja, Ph.D 
VCU School of Medicine 
Division of Cardiology 
 
 
 
 
Phosphodiesterase-5 inhibitor, sildenafil (SIL) protects against myocardial 
ischemia/reperfusion (I-R) injury.  We hypothesized that SIL-induced protection may be 
mediated through activation of SIRT1, an enzyme which deacetylates proteins involved in 
cellular stress response.  Adult male ICR mice were treated with SIL (0.7mg/kg ip), 
Resveratrol (RSV) (5mg/kg ip) (positive control), or saline (0.2 ml ip). The hearts were 
xii 
harvested 24 h later and homogenized for SIRT1 activity analysis. Both SIL and RSV 
increased cardiac SIRT1 activity (P<0.001) as compared to Saline.  Adult mouse 
ventricular cardiomyocytes pre-treated with either SIL or RSV (1µM) in vitro also 
upregulated SIRT1 activity (P<0.05).  SIL also reduced infarct size following 30 min. 
ischemia and 24 h reperfusion in vivo. Sirtinol (5mg/kg  in 10% DMSO, ip), a SIRT1 
inhibitor abolished the infarct-limiting effect of SIL and RSV (P<0.001).  In conclusion, 
activation of SIRT1 by SIL plays an essential role in cardioprotection against I-R injury.   
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INTRODUCTION 
 
 
1.1 Cardiovascular Disease and Myocardial Ischemia/Reperfusion Injury: 
According to the World Health Organization, cardiovascular disease ranks number one 
among the causes of death and is projected to remain the leading cause of death worldwide. 
Cardiovascular disease accounts for approximately 1 million deaths in the United States 
annually.  There are an estimated 62 million people with cardiovascular disease and 50 
million people with hypertension in this country.1 The greatest affected population is over 
the age of 65.  It is expected that as the population continues to age, and life expectancy 
continues to increase, there will be a growing population of people afflicted with heart 
conditions requiring costly health care interventions such as coronary bypass graft surgery 
and angioplasty.2  Heart related conditions can lead to other organ damage, and can 
become very costly and debilitating for the patient.   
Acute myocardial ischemia (AMI) is a cardiovascular disease that affects an 
estimated 1.5 million people in the United States annually and is a major cause of mortality 
and morbidity worldwide.  Over half of the patients with AMI die within one hour of the 
event.  AMI occurs when there is a sudden occlusion of an artery supplying blood to 
myocardium, depriving the area of blood, oxygen and nutrients, and causing dramatic 
changes in the cellular metabolism and function within the tissue.  Myocardial infarction 
can cause severe cellular and tissue damage such as myocyte hypertrophy, myocyte death, 
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and disruption of matrix metalloproteinase balance.  Following myocardial ischemia, there 
is a loss of contracting myocardium and a resulting increase in the workload on the viable 
myocardium.  The cardiac overload caused by myocardial infarction increases energy 
utilization and supply-demand imbalance, which lead to cellular necrosis and apoptosis.  
This subsequently leads to remodeling and worsening of left ventricular function, and 
eventually heart failure.3    
 
1.2 Ischemic and Pharmacological Preconditioning: 
Ischemic Preconditioning (IP) is an innate mechanism used to protect against I-R injury by 
simulating angina in the clinical setting.  IP was first documented in 1986 after 
experiments were conducted in a canine heart by Murry et. al. It was found that brief 
episodes of ischemia can protect the heart from a subsequent prolonged ischemic episode. 
10, 11  12, 13  IP has been shown to reduce myocardial infarct size as well as the extent of 
damage to skeletal muscle, brain or hepatic tissue induced by subsequent exposure to 
severe ischemia in a variety of species.10, 12  
 Two different phases of IP cardioprotection have been observed, the early phase 
and the late phase.  The early phase is referred to as “classic” preconditioning which is 
observed immediately after brief periods of ischemia and lasts for approximately 1-2 
hours.10, 11  The second phase is referred to as the “delayed” phase of preconditioning, and 
is observed at 12 hours following a brief ischemic insult and lasts up to 96 hours.10, 11 The 
late phase of preconditioning has been the focus of most studies because of the potential to 
exploit the protective mechanisms against ischemic heart disease in patients.2, 13  
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 Several intracellular signaling pathways and receptors have been found to be 
involved in the cardioprotective effect of preconditioning.  Endogenous mediators such as 
adenosine, catecholamines such as norepinephrine, opiods, free radicals, and bradykinin 
have all been shown to trigger preconditioning.8, 11  Proposed IP mechanisms include the 
release of these endogenous mediators, activation of G-coupled receptors and protein 
kinase C, the opening of mitochondrial KATP channels, and synthesis of cytoprotective 
proteins including endothelial nitric oxide synthase (eNOS), inducible nitric oxide synthase 
(iNOS), cyclooxygenase-2, and heat shock protein HSP70.12   
Pharmacological activators of the pathways involved in IP have been given 
exogenously and have been shown to exhibit cardioprotective effects as well.   However, 
few agents have been implemented in the clinical setting against ischemic heart disease.2   
Over the last 8 years, our laboratory has pioneered the concept that potent 
phosphodiesterase-5 (PDE-5) inhibitors, including Sildenafil (Viagra), Vardenafil (Levitra) 
and Tadalafil (Cialis), which are known to enhance erectile function in men induce 
powerful cardioprotective effect against I-R injury in the rabbit and mouse 
hearts21,48,myocardial ischemia-induced heart failure3 and doxorubicin-induced 
cardiomyopathy in mice.49  We also deomonstrated that the protective effect of SIL was 
dependent on the opening of ATP-sensitive mitochondrial (mitoKATP) channels.  Our 
hypothesis was that potent vasodilatory action of SIL (and other PDE-5 inhibitors) could 
potentially release endogenous mediators of IP including adenosine6, that may trigger 
receptor-mediated signaling cascade (through the action of kinases)9 resulting in 
phosphorylation of eNOS and release of NO.46 The generation of NO could potentially 
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activate guanylyl cyclase (GC) leading to enhanced formation of cGMP.  cGMP further 
activate protein kinase G (PKG) that can subsequently open mitoKATP channel resulting in 
cardioprotective effects.50  
 
1.3 SIRT1: 
In recent years, histone deacetylases (HDACs) have been shown to regulate cardiac 
hypertrophy and other cardiac diseases.33  There are three classes of HDACs that have 
been recognized in humans: class I and class II which are zinc-dependent amidohydrolases, 
and class III which are nicotinamide adenine dinucleotide (NAD+) -dependent.33  NAD+-
dependent deacetylases are also termed as sirtuins due to their homology with the yeast 
histone deacetylase Sir2.33  SIRT1 is part of the class III Sirtuin family of HDACs.  SIRT1 
catalyzes a reaction in which nicotinamide is liberated from NAD+ and the acetyl group of 
the substrate is transferred to cleaved NAD+, generating the novel metabolite O-acetyl-
ADP ribose.32, 34   
Since SIRT1 can deacetylate a variety of substrates, it is involved in a broad range 
of physiological functions.  The murine homolog of SIRT1 is Sir2.28  Mice deficient in 
Sir2 exhibit developmental abnormality in the heart and rarely survive postnatally, 
suggesting that Sir2 has important functions in the heart.28  Sirtuins have also been linked 
to cancer, muscle differentiation, inflammation, obesity, and neurodegeneration.4, 32   
SIRT1 has anti-aging effects, and has been shown to extend the life span in yeast and 
worms.32  SIRT1 has many proven biological functions including control of gene 
expression, cell cycle regulation, apoptosis, DNA repair, metabolism, oxidative stress 
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response and aging.35   SIRT1 activity has also been correlated with metabolic state of cells 
and it is believed to be nutrient regulated due in part to its dependency on NAD.32, 34, 36-38 
Unlike class I and II HDACs, SIRT1 deacetylates non-histone proteins such as Forkhead 
transcription factors (FOXO), peroxisome proliferation activating receptor (PPAR)-gamma 
co-activator-1α (PGC-1α), nuclear factor κB, myoD, ku70, and p53.27, 29, 30, 34  
 
1.4 Activator and Inhibitor of SIRT1: 
Resveratrol (RSV) is the best naturally occurring putative small molecule activator 
of SIRT127-30, which allosterically binds to SIRT1 and lowers the Michaelis constant of 
SIRT1 for both the acetylated substrate and NAD+.31, 32  RSV has been shown to be a 
pharmacological preconditioning agent which mimics ischemic preconditioning like effect 
in the kidney, heart, and brain against ischemic injury, however the mechanism of action 
remains unclear.   
Sirtinol is a putative inhibitor of SIRT1 and has been used as such extensively in 
literature.29, 32, 33  The aromatic ring moieties of the inhibitor interact with the hydrophobic 
potions of the residues Thr89, Lys287, Glu323, and Cys324 on SIRT1, which normally 
functions as the binding site for the adenine base of NAD+.33  When Sirtinol interacts with 
SIRT1, it prevents NAD+ from reacting thereby inhibiting SIRT1 functionality.   
 
1.5 SIRT1 and Cellular Stress Response: 
Stress resistance is a measure of the cells ability to survive under detrimental conditions.  
A number of proteins have been implicated in the stress response, including SIRT1.  
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‘Hormesis’ is the phenomenon in which a mild stress, such as IP, can induce a protective 
response against subsequent stresses.  This response is credited for how mildly stressed 
animals paradoxically outlive their unstressed peers.26  This has been demonstrated in 
calorie-restricted yeast, where mildly nutrient deprived yeast survived longer than the 
control.26  Caloric restriction is defined as a reduction of calorie intake, typically by 30–
40% in rodents, to a level that does not cause malnutrition and increases lifespan and stress 
resistance in multiple species.26  SIRT1 expression is upregulated in calorie restricted mice 
and 3- to 9-fold in response to cardiac stress in monkeys.35  The balance between growth 
and death in cardiac myocytes plays an important role in determining the pathophysiology 
of cardiac diseases.35  Cardiac myocytes can be transcriptionally reprogrammed in 
response to cellular stress.  Studies have shown antioxidants and heat shock protein 
expression increases as a cell protective mechanism.35  The amount of SIRT1 expression 
and activity upregulation is a compensatory mechanism, and has been shown to retard 
aging and inhibit apoptosis without causing NAD+ depletion or mitochondrial 
dysfunction.35  Research has shown that SIRT1 has been associated with RSV’s 
cardioprotective effect on myocyte survival following ischemia.30   SIRT1 expression is 
upregulated in response to proapoptotic stimuli.28  The mechanism by which SIRT1 is 
believed to protect cardiomyocytes from apoptosis is through inactivation of p53 by 
deacyetylation.39  SIRT1 is upregulated in response to stress in the heart such as pressure 
overload and paraquat injections which induce oxidative stress.35  SIRT1 upregulation has 
also been correlated with age, older monkey hearts had almost three times as much SIRT1 
upregulated when compared to young monkey hearts.35 
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SIRT1 is an important regulator of cell defenses and survival in response to 
stress.30, 32  SIRT1 represses p53-dependent apoptosis in response to oxidative stress and 
DNA damage.30   FOXO3 is a transcription factor deacetylated by SIRT1, that regulates 
several genes involved in reactive oxygen species (ROS) detoxification, cell cycle arrest 
(Cyclin D2), apoptosis, and DNA damage repair.  FOXO3a acts as a cellular stress sensor 
and mediates the stress response.16, 24  Studies have shown that in response to oxidative 
stress, SIRT1 and FOXO3 form a complex and the ability of FOXO3 to induce DNA 
damage repair and cell cycle arrest is enhanced.16, 24, 30  SIRT1 provides protection against 
apoptosis and has an essential role in mediating the survival of neurons and cardiac 
myocytes under stress in vitro.28  There is evidence that inhibition of SIRT1 activity in 
cardiomyocytes leads to an increase in the basal rate of apoptosis and upregulation of 
hypertrophy associated genes.4, 39  
 
1.6 PGC-1α and Myocardial I-R Injury: 
Mitochondria are the main energy sources of cells, and compromised mitochondrial 
function can lead to cardiovascular and metabolic diseases.25  Peroxisome proliferator-
activated receptor gamma, coactivator 1 alpha, also known as PPARGC1A and PGC-1α, is 
a gene that encodes for a gene that is a transcriptional coactivator that regulates 
transcription of genes involved in a wide variety of biological responses including 
mitochondrial biogenesis, adaptive thermogenesis, glucose/fatty acid metabolism, fiber 
type switching in skeletal muscle, and heart development.25, 34  Since PGC-1α controls 
mitochondrial biogenesis and function, it plays an important role in cell survival.  PGC-1α 
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may also play a key role in the attenuation of I-R injury since ischemia causes sequential 
changes in mitochondrial morphology in the myocardium.  Increased expression of PCG-
1α has been shown to increase mitochondrial biogenesis and oxidative metabolism.  When 
there is an increased demand for ATP and damage to mitochondrial integrity, it is expected 
that the expression of PGC-1α will also increase.   
MitoKATP channels act as metabolic sensors that regulate cellular activity according 
to cellular energetic demands, and the opening of these channels is necessary for the 
infarct-sparing effects of preconditioning.13, 42   Regulating mitochondrial membrane 
potential is a crucial component to cellular stress response.34  Upon a stress stimuli, PGC-
1α transiently enters the nucleus to activate transcription of target genes, and then PGC-1α 
is either degraded in the nucleus or returns to the cytoplasm.34  PGC-1α has been shown to 
be required for the adaptation to the stress-induced change in mitochondrial membrane 
potential.34  
 
1.7 SIRT1 and Heat Shock Response: 
The heat shock response (HSR) is the cellular response to stress.  The heat shock response 
was first recognized in response to elevated temperature, however it is an essential 
mechanism for the protection of cells in any type of cellular stress.  As part of the HSR, 
heat shock proteins (HSPs) are induced to act as molecular chaperones to repair damaged 
proteins.  HSP production can also be induced by non-stress biological stimuli such as 
growth factors and differentiation factors.  Therefore, HSPs have an important role in 
maintaining cellular homeostasis. HSPs are a set of highly conserved proteins with 
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molecular masses of 28, 60, 70, 82, 90, and 110 kDa.  The most abundant heat shock 
protein is HSP70.  These proteins are typically induced by stresses such as heat shock, 
ischemia, exposure to transition metals, pressure overload, and exposure to oxygen 
radicals.13  HSP70 has been shown to be a molecular chaperone that aids in 
cardioprotection against metabolic insults such as I-R injury.  The amount of HSP70 is 
directly proportional to the amount of cardioprotection against I-R injury.13  Studies in 
transgenic mice overexpressing HSP70 have shown that this protein confers protection 
against I-R injury.13  Myocardial HSP70 is upregulated 24 hours after IP.13  
Heat Shock Factor 1 (HSF1) is a gene that encodes a transcription factor that 
regulates gene expression in response to cellular stress, including the human HSP70 gene.  
Transient activation of HSF1 occurs through various environmental and physiological 
stresses.  The activation of HSF1 is a multi-step process in which an HSF1 monomer is 
converted to a DNA-binding trimer and becomes phosphorylated at serine residues.  For a 
brief time, HSF1 is capable of binding to DNA promoters and enhancing transcription.43  
In its deacetylated state, HSF1 can bind to DNA.  Activation of SIRT1 has been shown to 
prolong HSF1 binding to the heat shock promoter of HSP70.43  It was also shown that 
downregulation of SIRT1 attenuated the heat shock response (HSR), and release of HSF1 
from its promoter elements.43  Therefore, the abundance and activity of SIRT1 was shown 
to regulate the attenuation of the HSR.43  SIRT1 has a central role in the maintenance of 
protein homeostasis and mediating the stress response.43  
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1.8 Rationale for the Present Study 
The aim of this study was to determine if SIL induces protection against I-R through 
increased expression and activation of SIRT1.  The secondary purpose was to determine 
the effect of SIL on eNOS, iNOS, HSP70, HSF1, and PGC-1α expression.  We 
hypothesized that SIRT1 expression and activity is necessary for the cardioprotective 
effects of SIL due to the overlap of signaling pathways involved the cellular response to I-
R injury.  RSV, a known pharmacological preconditioning agent, is one of the most potent 
small molecule activators of SIRT1, and was used as a positive control in all of the studies.  
If SIL increases SIRT1 activity and/or expression, it may indicate that SIL has other 
possible therapeutic benefits. 
 To test this hypothesis we used a murine model of  I-R where we occluded left 
coronary artery for 30 minutes and reperfused the heart for 24 hours.  The effect of 
treatment with SIL was compared to that with RSV and a Saline control.  Sirtinol was 
administered with SIL to determine if the use of a SIRT1 inhibitor would abolish protein 
expression, protein activity, and cardiac remodeling normally present upon treatment with 
SIL alone.   
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MATERIALS AND METHODS 
 
2.1 Animals: 
Adult male ICR mice weighing 35.5 ± 5g were supplied by Harlan Sprague 
Dawley Co. (Indianapolis, IN). All animal experiments were conducted under the 
guidelines on humane use and care of laboratory animals for biomedical research 
published by the U.S. National Institutes of Health (NIH Publication No. 85-23, revised 
1996). All experimental preparations and protocols involving animals were reviewed and 
approved by the Animal Care and Use Committee of Virginia Commonwealth University. 
 
2.2 Antibodies and Chemicals:  
SIRT1 (Sigma-Aldrich, St. Louis, MO), HSP70 (Santa Cruz Biotechnology), PGC-1α 
(GenWay, San Diego), HSF1 (Santa Cruz Biotechnology), eNOS (Santa Cruz 
Biotechnology), iNOS (Santa Cruz Biotechnology), donkey anti-goat IgG-HRP (Santa 
Cruz Biotechnology), donkey anti-rabbit IgG (Amersham) and β-Actin (Santa Cruz 
Biotechnology) were used for Western blots.  SIRT1 (Cyclex) and Protein A agarose beads 
were used for Immunoprecipitation.  Triphenyltetrazolium chloride (TTC) and Formalin 
were purchased from Sigma-Aldrich (St. Louis, MO)   
 
 
12 
2.3 Drug Preparation:  
Trans-Resveratrol powder was purchased from Sigma-Aldrich (St. Louis, MO) and was 
dissolved in 15% dimethyl sulfoxide (DMSO) and saline (0.9% NaCl containing 2.5 mM 
CaCl2) for intraperitoneal (ip) injection.  Sildenafil citrate powder was kindly provided by 
Pfizer and was dissolved in saline for ip injection.   Sirtinol was purchased from Sigma-
Aldrich (St. Louis, MO) and was dissolved in 10% warm PBS and sonicated until 
homogenous.44  Final concentrations of the drugs injected in ICR mice ip were 0.7mg/kg, 
5mg/kg, and 5mg/kg for SIL, RSV, and Sirtinol respectively.   The SIL dose of 0.7 mg/kg 
ip was chosen to simulate the serum level of SIL for a patient with 70 kg body weight after 
orally taking a l00 mg tablet of SIL.2, 26  The therapeutic dose range for SIL is 25 to 100 
mg once a day.17  Although the plasma half-life of SIL is only 4 hours, the therapeutic 
benefits have been documented up to 24 hours after administration.17  The doses of RSV 
and Sirtinol were determined based on a previous study where these drugs were 
administered ip.44   
 
2.4 Myocardial infarction protocol:  
Surgical procedures were followed as previously reported.3  In brief, the animals were 
anesthetized with the injection of pentobarbital sodium (70 mg/kg ip), intubated 
orotracheally, and ventilated on a positive-pressure ventilator. The tidal volume was set at 
0.2 ml, and the respiratory rate was adjusted to 133 cycles/min. All surgical procedures 
were carried out under sterile conditions. A left thoracotomy was performed at the fourth 
intercostal space, and the heart was exposed by stripping the pericardium. The left anterior 
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descending coronary artery (LAD) was then identified and occluded for 30 minutes by a 
7.0 silk ligature that was placed around it with a small tube occluding flow.  After 30 
minutes of ischemia the tube was removed to reperfuse the tissue.  The air was expelled 
from the chest.3  Infarct size, protein expression, or protein activity was measured from the 
heart harvested after 24 h of reperfusion.   
Survival. Animals that died during the surgical procedure or during recovery were 
excluded.  
Experimental Protocol 1: Infarct Size Assessment.  (See Figure 1)  In these studies, SIL 
(0.7 mg/kg), RSV (5 mg/kg), or Saline (volume matched 0.2ml) was given ip in ICR mice 
and 24 h later, the mice were subjected to ischemia and reperfusion.  In SIRT1 inhibitor 
studies, the ICR mice were given an initial ip injection of either SIL (0.7 mg/kg), RSV (5 
mg/kg in 15% DMSO), or Saline (volume matched 0.2ml), and 24 h later given either 
Sirtinol (5 mg/kg in 10% DMSO) or 10% DMSO in warm PBS (volume matched 0.2ml) 
30 minutes prior to I-R.  24 h after reperfusion Infarct size was determined.  This was a 
single-blind study, where the surgeon was blinded to the type of drug administered to the 
mice.   
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Figure 1. Experimental Protocol 1. ip injections were given as follows: Group I: Saline 
(volume matched, 0.2ml); Group II: Resveratrol (5mg/kg, 0.2ml); Group III: Sildenafil 
(0.7mg/kg, 0.2ml); Group IV: Saline (volume matched, 0.2ml) and Sirtinol (5 mg/kg, 
0.2ml); Group V: Resveratrol (5mg/kg, 0.2ml) and Sirtinol (5 mg/kg, 0.2ml); Group VI: 
Sildenafil (0.7mg/kg, 0.2ml) and Sirtinol (5 mg/kg, 0.2ml); Group VII: Saline (0.2ml) and 
DMSO (%10 in warm PBS, 0.2ml); Group VIII: Resveratrol (5mg/kg, 0.2ml) and DMSO 
(%10 in warm PBS, 0.2ml); Group IX: Sildenafil (0.7mg/kg, 0.2ml) and DMSO (%10 in 
warm PBS, 0.2ml) 
 
 
     Group I, II, III 
Group IV, V, VI 
 
 
Sirtinol (5mg/kg in 10% 
DMSO, 0.2ml ip) 
 
Group VII, VIII, IX 
 
10% DMSO in warm PBS 
(0.2ml ip) 
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Experimental Protocol 2: Protein Expression and Activity Assessment following I-R.  (See 
Figure 2)  In these studies, SIL (0.7 mg/kg), RSV (5 mg/kg), or Saline (volume matched 
0.2ml) was given ip in ICR mice and 24 h later the mice were subjected to 30 minutes of 
ischemia and 24 h of reperfusion.  Sham mice were used as a control for surgical 
conditions, and all of the same procedures were followed except instead of ligating the 
LAD, a 7.0 silk suture was passed underneath the LAD and removed immediately.  In 
SIRT1 inhibitor studies only SIRT1 activity was measured, the ICR mice were given an 
initial ip injection of either SIL (0.7 mg/kg), RSV (5 mg/kg in 15% DMSO), or Saline 
(volume matched 0.2ml), and 24 h later given either Sirtinol (5 mg/kg in 10% DMSO) or 
10% DMSO in warm PBS (volume matched 0.2ml) 30 minutes prior to I-R.  The mice 
were anesthetized with the injection of pentobarbital sodium (70 mg/kg ip), their hearts 
were removed, and frozen at -80 degrees Celsius until use.   
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Figure 2. Experimental Protocol 2. ip injections were given as follows: Group I: Saline 
(volume matched, 0.2ml); Group II: Resveratrol (5mg/kg, 0.2ml); Group III: Sildenafil 
(0.7mg/kg, 0.2ml); Group IV: Saline (volume matched, 0.2ml) and Sirtinol (5 mg/kg, 
0.2ml); Group V: Resveratrol (5mg/kg, 0.2ml) and Sirtinol (5 mg/kg, 0.2ml); Group VI: 
Sildenafil (0.7mg/kg, 0.2ml) and Sirtinol (5 mg/kg, 0.2ml); Group VII: Saline (0.2ml) and 
DMSO (%10 in warm PBS, 0.2ml) The mice were anesthetized with the injection of 
pentobarbital sodium (70 mg/kg ip), their hearts were removed, and frozen at -80 degrees 
Celsius until use.   
 
 
Group I, II, III 
 
Sacrifice Mouse and 
collect sample  
Group IV, V, VI 
 
 
Sirtinol (5mg/kg in 10% 
DMSO) 
Sacrifice Mouse and 
collect sample  
Group VII 
 
 
10% DMSO 
Sacrifice Mouse and 
collect sample  
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2.5 Measurement of Infarct Size and Risk Area: 
Infarct Size and Risk Area were determined using methods similar to those 
previously reported.3, 45  At the end of reperfusion, the mouse was anesthetized with the 
injection of pentobarbital sodium (70 mg/kg ip).  The heart was excised from the mouse 
and mounted on a Langendorff apparatus. The coronary arteries were perfused with 0.9% 
NaCl containing 2.5 mM CaCl2. After the blood was washed out, 2 ml of 10% Evans blue 
dye were injected as a bolus into the aorta until most of the heart turned blue. The heart was 
perfused with saline to wash out the excess Evans blue. The stained heart was removed 
from the Langendorff apparatus and frozen at -20 °C. The frozen heart was cut into six to 
eight transverse slices.  The slices were placed onto an inverted petri dish (Becton 
Dickinson Labware) and put face down into the inverted cover of the same petri dish. The 
heart slices were stained by incubating them in 10% 2, 3, 5-triphenyl tetrazolium chloride 
(TTC, Sigma) solution for 30 minutes at room temperature (~22°C). The infarct area and 
risk area was measured using computer morphometry (Bioquant 98). The risk area was 
calculated as total ventricular area minus the area of the cavities. The infarct size was 
presented as percentage of the risk area (See Figure 3).  
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Figure 3. Representative section of mouse heart.  This cross section shows the criteria 
used to determine the risk area, non-risk area, infracted tissue, cavity area, and viable 
tissue.  The risk area was calculated as total ventricular area minus the area of the cavities. 
The infarct size was presented as percentage of the risk area.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Viable Tissue (Red) 
Cavity Area 
Infarcted Tissue (Pale) Non-Risk Area (Blue) 
Right Ventricle 
Risk Area (Pink Line) 
Left Ventricle (Red Line) 
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2.6 Assessment of Heart Function:  
 Doppler Echocardiography was performed using the Vevo770TM imaging system 
(VisualSonics Inc., Toronto, Canada) prior to surgery (baseline), and after 24 hours of 
reperfusion using techniques similar to those previously reported.3  Mice were anesthetized 
with pentobarbital sodium (30 mg/kg ip). The mice were placed in the supine position, and 
ECG limb electrodes were attached. The chest was carefully shaved, and ultrasound gel 
was used on the thorax to optimize visibility during the exam. A 30-MHz probe was used 
to obtain two-dimensional (B-Mode), and cross-sectional (M-mode) imaging from 
parasternal short-axis view at the level of the papillary muscles.  M-mode images of the LV 
were obtained, and systolic and diastolic wall thickness (anterior and posterior) and LV 
end-systolic and end-diastolic diameters (LVESD and LVEDD, respectively), Ejection 
Fraction (EF), Fractional Shortening (FS), and heart rate (HR) were measured.  
 
2.7 Healthy Heart Harvestation: 
Studies were also performed to determine the activity of SIRT1 and expression of SIRT1, 
HSP70, PGC-1α, HSF1, eNOS, and iNOS in healthy ICR mice hearts following treatment 
with SIL.   
Experimental Protocol 3: Protein Expression and Activity Assessment 24 h after pre-
treatment.  (See Figure 4)  In these studies, SIL (0.7 mg/kg), RSV (5 mg/kg), or Saline 
(volume matched 0.2ml) was given ip in ICR mice and 24 h later, the mice hearts were 
harvested for expression and activity assays. The mice were anesthetized with the injection 
20 
of pentobarbital sodium (70 mg/kg ip), their hearts were removed, and frozen at -80 
degrees Celsius until use.      
Experimental Protocol 4. SIRT1 Activity Assessment after 7 days of pre-treatment.  In 
these studies, SIL (0.7 mg/kg), SIL (1.4 mg/kg), RSV (5 mg/kg), or Saline (volume 
matched 0.2ml) was given ip in ICR mice twice a day, once in the morning and once in the 
evening, for a period of one week.  After 7 days, the mice were anesthetized with the 
injection of pentobarbital sodium (70 mg/kg ip), their hearts were removed, and frozen at -
80 degrees Celsius until use.   
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Figure 4. Experimental Protocol 3: Protein Expression and Activity Assessment 24 h after 
pre-treatment. ip injections were given as follows: Group I: Saline (volume matched, 
0.2ml); Group II: Resveratrol (5mg/kg, 0.2ml); Group III: Sildenafil (0.7mg/kg, 0.2ml) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Group I, II, III 
Sacrifice Mouse and 
collect sample  
22 
2.8 Isolation of Ventricular Cardiomyocytes: 
The ventricular cardiomyocytes were isolated using an enzymatic technique similar to a 
previously reported method.46  In brief, the mouse was anesthetized with the injection of 
pentobarbital sodium (70 mg/kg ip), and the heart was quickly removed from the chest. 
Within 3 min, the aorta was cannulated onto a Langendorff apparatus, and the heart was 
retrogradely perfused (37 °C) at a constant pressure of 55 mm Hg for 5 min with a Ca2+-
free bicarbonate-based buffer containing 120 mM NaCl, 5.4 mM KCl, 1.2 mM MgSO4, 1.2 
mM NaH2PO4, 5.6 mM glucose, 20 mM NaHCO3, 10 mM 2,3-butanedione monoxime, and 
5 mM taurine that was continuously gassed with 95% O2 + 5% CO2. The enzymatic 
digestion was started by adding collagenase type II (Worthington; 0.5 mg/ml each) and 
protease type XIV (0.02 mg/ml) to the perfusion buffer and continued for 15 min. 50 µM 
Ca2+ was then added in to the enzyme solution for perfusing the heart for another 10–15 
min. The digested ventricular tissue was cut into small pieces and gently aspirated with a 
transfer pipette for facilitating the cell dissociation. The cell pellet was resuspended for a 
three-step Ca2+ restoration procedure (i.e. 125, 250, and 500 µM Ca2+). The freshly isolated 
cardiomyocytes were then suspended in minimal essential medium (catalogue number 
M1018, pH 7.35–7.45; Sigma) containing 1.2 mM Ca2+, 12 mM NaHCO3, 2.5% fetal 
bovine serum, and 1% penicillin-streptomycin. The cells were then plated onto 35-mm cell 
culture dishes that were precoated with 20 µg/ml mouse laminin in phosphate-buffered 
saline with 1% penicillin-streptomycin for 1 h. After 1 h of plating, the cardiomyocytes 
were incubated with 1uM SIL, 1uM RSV, or without the drugs (control).  The cells were 
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scraped from the plate following incubation and frozen at -80 degrees Celsius until used 
for SIRT1 activity analysis and protein expression analysis. 
 
2.9 Western blot analysis for SIRT1, HSP70, HSF1, eNOS, iNOS, and PGC-1α: 
Homogenization and Protein Extraction:  The murine hearts were homogenized and 
protein expression was analyzed using techniques similar to a previously reported 
method.45  In brief, the hearts were removed from the -80 degree Celsius freezer and a 
mortar and pestle were used to grind the heart into fine pieces.  Total soluble protein was 
extracted from the myocytes and whole heart lysates with extraction buffer containing 
RIPA buffer, PMSF, Protease Inhibitor, Na3VO4, and β-mercaptoethanol. A mechanical 
homogenizer was used to further homogenize the samples, then the samples were sonicated 
and left on ice for 30 minutes.  The homogenate was then centrifuged at 14,000 x g for 15 
min under 4 °C and the supernatant was recovered. The supernatant was frozen at -80 
degrees Celsius until used.  The protein amount was quantified using a Bio-Rad assay. 100 
µg of protein from each sample was separated by SDS-PAGE on a 7.5% polyacrylamide 
gel, transferred onto nitrocellulose membrane and then blocked with 5% nonfat dry milk in 
TBST (10 mM Tris-HCl, pH 7.4, 100 mM NaCl, and 0.1% Tween 20) for 1 h.  The 
membrane was incubated with primary antibody at a dilution of 1:1000 for each of the 
respective proteins, i.e. SIRT1, HSP70, HSF1, eNOS, iNOS, PGC-1α, and β-actin 
overnight at 4 degrees Celsius or at room temperature for 2 h. The membrane was washed 
with TBST and incubated with the appropriate secondary antibody (1:2000 dilution, 1 h at 
room temperature). The blots were developed using a chemiluminescent system (ECL Plus; 
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Amersham Biosciences).  Densitometry was used to quantify the optical density for each 
band and was normalized with the intensity of β-actin.46  
 
2.10 Protein purification of SIRT1 for deacetylase activity analysis: 
Homogenization and Protein Extraction: The sample preparation techniques used were 
previously reported.24  In brief, the hearts were removed from the freezer, and ground with 
a mortar and pestle in liquid nitrogen.  The tissues were homogenized mechanically in a 
lysis buffer containing 10 mM Tris-HCl (pH 7.4); NP-40 0.5%; 250 mM sucrose; 0.1mM 
EGTA; 10mM NaCl; 15 mM MgCl2; 1 mM PMSF; 1 mM Na3VO4; and 1 mM NaF. The 
tissue homogenates (without protease inhibitors) were spun through 4 mL of sucrose 30%, 
10 mM Tris HCl (pH 7.5), 10 mM NaCl, and 3 mM MgCl2 at 1,300 x g for 10 min at 4°C; 
the pellet was washed with cold 10 mM Tris-HCl (pH 7.5) and 10 mM NaCl. The nuclei 
were suspended in 100 uL of extraction buffer containing 50 mM Hepes KOH (pH 7.5), 
420 mM NaCl, 0.5 mM EDTA Na2, 0.1 mM EGTA, and glycerol 10%, sonicated for 30 s, 
and stood on ice for 30 min. After centrifugation at 13,000 rpm for 10 min, an aliquot of 
the supernatant (crude extract nuclear) was used to determine protein concentration using a 
Bio-Rad assay.24  
Immunoprecipitation.  The samples were immunoprecipitated with SIRT1 antibody 
according to the manufacturers’ instructions.  1 μg of SIRT1 primary antibody (Cyclex) 
was incubated with 250µg of protein in extraction buffer (total volume 200ul) overnight at 
4 degrees Celsius.  Protein A agarose beads were then incubated with the mixture 
overnight at 4 degrees C.  The mixture was then microcentrifuged for 30 seconds at 4 
25 
degrees Celsius.  The pellet was washed three times with 250 ul of 1x Cell Lysis Buffer 
(Cyclex) and 250 ul of Sir2 assay buffer (50 mM Tris-HCl, pH 8.8, 4 mM MgCl2, 0.5 mM 
DTT).  The pellet was then suspended in 100ul of Sir2 assay buffer and kept frozen at -20 
degrees Celsius until use.   
 
2.11 SIRT1 deacetylase activity assay: 
SIRT1 deacetylase activity was evaluated in the whole heart lysates as well as myocyte 
lysates from the ICR mice according to the manufacturers’ protocols with a few 
modifications. We measured SIRT1 using a deacetylase fluorometric assay kit (Sir2 Assay 
Kit, CycLex, Ina, Nagano, Japan). The final reaction mixture (100 uL) contained 50 mM 
Tris-HCl (pH 8.8), 4 mM MgCl2, 0.5 mM DTT, 0.25 mA/mL Lysyl endopeptidase, 1uM 
Trichostatin A, 200 uM NAD, and 10 uL of crude extract nuclear sample. The fluorescence 
intensity at 440 nm (exc.340 nm) was measured every 5 minutes for a total of 30 min 
immediately after the addition of fluorosubstrate peptide, and then once immediately after 
the addition of stop solution.  60uM of Sirtinol was used as the inhibitor of SIRT12432, and 
Trichostatin A (TSA) was used as an inhibitor of class I and class II HDACS.28  All 
determinations were performed in duplicate and the results are reported as relative 
fluorescence (Arbitrary Units).24  
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2.12 Data analysis and statistics: 
Data are presented as mean ± S.E. The differences between groups were analyzed with one-
way analysis of variance followed by Student-Newman-Keuls post hoc test for pair-wise 
comparison. p < 0.05 was considered to be statistically significant.45   
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RESULTS 
 
 
 
 
3.1 Exclusions 
 A total of 167 hearts were used in all of the experimental protocols.  Among these, 
35 hearts were excluded due to one or more of the following reasons: death during any 
portion of the surgical procedure, damage to the aorta during cannulation, and longer 
cannulation time (greater than 3 min).  Seven mice passed away when Sirtinol was 
dissolved in 100% DMSO and administered via ip injection to the mice.  The overall 
mortality rate was 21%.  Mice were randomly assigned to groups in different experimental 
protocols.   
 
3.2 Sildenafil and Resveratrol preconditioning reduced infarct size 
 Previous studies have established the cardioprotective effects of SIL and RSV on 
infarct size following I-R injury.3, 6, 14-16  Our results confirm previous results as shown in 
Figure 5.  As shown in Figure 5A, the infarct size of the Saline control mice was 48.3 ± 
5.9% (n = 6) of the risk area.  SIL significantly (P<0.001) reduced infarct size to 22.3 ± 
7.6% (n = 6) of the risk area in mice, which caused a 53.8% infarct size reduction when 
administered 24 hours prior to I-R injury compared to the saline controls.  RSV, a putative 
activator of SIRT1, also significantly (P<0.001) reduced infarct size to 17.4 ± 3.7% (n = 6) 
28 
of the risk area in mice, which was a 64.0% reduction compared to saline controls.  Since 
Sirtinol was dissolved in 10% DMSO, three groups were included in the study to control 
for the possible effects of DMSO solvent.  Infarct size in the Sirtinol vehicle controls 
(Saline + DMSO, RSV + DMSO, and SIL + DMSO) were not statistically significantly 
different (P>0.05) from the drugs administered alone (See Figure 5A).   
 
 
 
 
 
 
 
 
29 
 
 
Figure 5. A. Myocardial Infarct Size.  Adult male ICR mice were randomly divided into 
9 groups as described in chapter 2.4, Figure 1.  Infarct size was significantly (P<0.001 vs. 
saline controls) reduced in the Sildenafil-treated, Resveratrol-treated, Sildenafil + DMSO-
treated, and Resveratrol + DMSO-treated groups.  Sirtinol abolished the cardioprotective 
effects of both Sildenafil and Resveratrol.  n = 6/Group, * = P< 0.001 vs. Saline Controls, 
# = P < 0.05 vs. other groups 
(n = 6/Group, * = P < 0.001 vs. Saline Controls,  
# = P < 0.05 vs. other groups) 
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Figure 5B. Myocardial Risk Area.  The total risk area was determined to be the 
percentage of the total left ventricular area that underwent ischemia.  n = 6/Group, P>0.05 
between all groups. 
Risk Area (% Left Ventricle)
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3.3 Sirtinol blocked the Preconditioning effect of Sildenafil and Resveratrol 
 Sirtinol is a widely used putative inhibitor of SIRT1.24  The pharmacological 
preconditioning effects of Resveratrol are believed to be through the activation of SIRT1.  
To verify the potential role of SIRT1 in SIL induced cardioprotection, Sirtinol was 
administered to the mice via interperitoneal injection 30 minutes prior to ischemia.   
Sirtinol abrogated the cardioprotective effect of 24 h pretreatment with Sildenafil and 24 h 
pretreatment with Resveratrol as shown in Figure 5A.  The infarct sizes of SIL + Sirtinol 
treated mice (38.9 ± 2.5% of risk area, n = 6) and RSV + Sirtinol treated mice (37.1 ± 
1.8% of risk area, n = 6) were not statistically significantly different (P>0.05) from mice 
treated with Saline (48.3 ± 5.9% of risk area, n = 6) or Saline + Sirtinol (52.5 ± 1.2% of 
risk area, n = 6).  The infarct sizes of SIL + Sirtinol treated mice were 74.2% greater than 
the infarct sizes of SIL treated mice (n = 6).  Also, as expected, the infarct sizes of RSV + 
Sirtinol treated mice were 113.3% greater than the infarct sizes of RSV treated mice (n = 
6).   
 
3.4 Sildenafil increased SIRT1 activity in vivo and in vitro 
 The effect of SIL on SIRT1 activity was investigated by measuring the relative 
fluorescence of deacetylated SIRT1 substrate (arbitrary units) in homogenized heart 
samples of ICR mice.   
ICR mice treated with Saline, RSV, or SIL 24 h prior to harvesting their hearts 
were analyzed for SIRT1 activity.  As shown in Figure 6, there was a significant increase 
in SIRT1 activity following SIL and RSV pre-treatment vs. Saline controls (P<0.001).  
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ICR mice were treated twice a day for seven days with Saline, RSV, or SIL (See Materials 
and Methods: Experimental Protocol 4), then sacrificed to harvest their hearts.  As shown 
in Figure 7, there was a significant increase in SIRT1 activity in the SIL-treated and RSV-
treated mice compared to Saline-treated mice.  There was not a significant difference 
(P>0.05) of SIRT1 activity between mice given 0.7mg/kg SIL ip twice daily vs. 1.4 mg/kg 
SIL ip twice daily administered for 7 days.  The difference between SIRT1 activity in SIL-
treated and RSV-treated mice was not statistically significant (P>0.05).   
In another study, ICR mice were pretreated with Saline, RSV, and SIL 24 hours 
prior to I-R injury, given Sirtinol 30 minutes prior to I-R, and their hearts were harvested 
after 24 hours of reperfusion (See Figure 2, Experimental Protocol 2).  There was a 
significant difference in the SIRT1 activity observed between RSV-treated I-R mice and 
SIL-treated I-R mice versus the Saline treated controls (P<0.0001).  The SIRT1 activities 
of RSV-treated and SIL-treated mice were also significantly different (P<0.05) than the 
SIRT1 activity of Saline I-R, RSV I-R, and SIL I-R mice (See Figure 8).  The direct affect 
of SIL on SIRT1 activity was also investigated in an in vitro mouse cardiomyocyte model.  
The adult ICR mice cardiomyocytes were incubated under 37°C and 5% CO2, for 1 h with 
1uM SIL, 1uM RSV, or without any drugs (See Materials and Methods, 2.8 Isolation of 
Ventricular Cardiomyocytes).  The results are shown in Figure 9.  The relative 
fluorescence of deacetylated SIRT1 substrate in myocytes treated with Sildenafil was 
450% greater than the control.   
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Figure 6. SIRT1 deacetylase activity in homogenized murine hearts following  24 h of 
Saline, RSV (5 mg/kg), SIL (0.7 mg/kg), and SIL (1.4 mg/kg) ip administration twice a 
day. n = 3/Group, * = P<0.001 vs. Saline. 
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Figure 7. SIRT1 deacetylase activity in homogenized murine hearts following 7 days of 
Saline, RSV (5 mg/kg), SIL (0.7 mg/kg), and SIL (1.4 mg/kg) ip administration twice a 
day. n = 3/Group, * = P<0.0001 vs. Control 
 
 
 
SIRT1 Activity 7 days
after Pre-Treatment
Sa
lin
e
RS
V (
5 m
g/k
g)
SIL
 (0
.7 
mg
/kg
)
SIL
 (1
.4 
mg
/kg
)
0
200
400
600
R
el
at
iv
e 
Fl
ou
re
sc
en
ce
 o
f
D
ea
ce
ty
la
te
d 
Su
bs
tr
at
e 
(A
.U
.)
(n = 3/Group, * = P < 0.0001 vs. Control) 
* * * 
35 
 
 
Figure 8.  SIRT1 deacetylase activity in homogenized murine hearts pretreated with 
Saline, RSV (5 mg/kg), and SIL (0.7 mg/kg) 24 hours prior to I-R injury, given Sirtinol (5 
mg/kg) 30 minutes prior to I-R, and harvested after 24 hours of reperfusion.  Sham mice 
were used as surgical controls, Saline treated mice were used as drug vehicle controls, and 
DMSO was used as the Sirtinol vehicle control.  n = 3/Group, * = P<0.0001 vs. Controls, # 
= P < 0.05 vs. other groups. 
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Figure 9.  SIRT1 deacetylase activity in murine cardiac myocytes following 1 h treatment 
with RSV (1µM), SIL (1µM), or no drug (control).  n = 2-3/Group, * P<0.05 vs. Control. 
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3.5 Cardiovascular function 
Doppler echocardiography was used to measure several parameters of left ventricular 
function in mice treated with drugs according to the experimental Figure 1 at baseline (pre-
ischemia) and 24 hours post-reperfusion.  These included end-diastolic diameter 
(LVEDD), left ventricular end-systolic diameter (LVESD), anterior wall diastolic 
thickness (AWDT), anterior wall systolic thickness (AWST), posterior wall diastolic 
thickness (PWDT), posterior wall systolic thickness (PWST), fractional shortening (FS), 
heart rate (HR), and ejection fraction (EF).   All preintervention baseline values were 
similar and not statistically significantly different (P>0.05) for all the sample groups in all 
of the Doppler echocardiography measurements for cardiovascular function.  (See Table 1 
and 2)   
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LVEDD 
(mm) 
LVESD 
(mm) 
AWDT 
(mm) 
AWST 
(mm) 
PWDT 
(mm) 
PWST 
(mm) 
Sham               
  Baseline 3.80 ± 0.32 2.53 ± 0.25 0.99 ± 0.05 1.37 ± 0.13 0.85 ± 0.17  1.23 ± 0.19 
  Post I-R 3.56 ± 0.48  2.56 ± 0.62 0.93 ± 0.13 1.18 ± 0.14 0.89 ± 0.12  1.14 ± 0.30 
DMSO               
  Baseline 4.2 ± 0.09 3.18 ± 0.11 0.85 ± 0.08 1.19 ± 0.11 0.89 ± 0.04 1.17 ± 0.07 
  Post I-R 4.4 ± 0.28 3.70 ± 0.49 0.89 ± 0.21 1.00 ± 0.35 0.92 ± 0.17 1.11 ± 0.07 
Saline               
  Baseline 3.80 ± 0.68 2.55 ± 0.11 0.91 ± 0.8 1.36 ± 0.41 0.84 ± 0.44 1.27 ± 0.61 
  Post I-R 3.99 ± 0.77 3.02 ± 0.65 0.95 ± 0.12 1.27 ± 0.08 0.99 ± 0.23 1.57 ± 0.67 
RSV               
  Baseline 3.55 ± 0.39 2.46 ± 0.36 0.76 ± 0.25 1.15 ± 0.19 1.07 ± 0.25 1.31 ± 0.24 
  Post I-R 3.57 ± 0.40 2.51 ± 0.43 0.90 ± 0.07 1.30 ± 0.16  1.19 ± 0.43 1.48 ± 0.48 
SIL               
  Baseline 3.94 ± 0.17 2.26 ± 0.34 0.92 ± 0.30 1.49 ± 0.41 0.9 ± 0.42 1.41 ± 0.39 
  Post I-R 3.61 ± 0.16 2.67 ± 0.15 0.80 ± 0.17 0.98 ± 0.14 0.95 ± 0.31 1.29 ± 0.28 
Saline + Sirtinol               
  Baseline 3.86 ± 0.38 2.6 ± 0.50 0.81 ± 0.04 1.21 ± 0.16  0.83 ± 0.04 1.17 ± 0.13 
  Post I-R 3.66 ± 0.19  2.78 ± 0.26 0.92 ± 0.20 1.20 ± 0.28 1.14 ± 0.11 1.28 ± 0.19 
RSV + Sirtinol               
  Baseline 3.84 ± 0.32 2.84 ± 0.35 0.82 ± 0.05 1.16 ± 0.05 0.82 ± 0.16 1.02 ± 0.21 
  Post I-R 3.99 ± 0.32 3.38 ± 0.38 0.96 ± 0.22 1.19 ± 0.25 1.01 ± 0.19 1.17 ± 0.27 
SIL + Sirtinol               
  Baseline 4.11 ± 0.082 3.06 ± 0.09 0.69 ± 0.11 0.95 ± 0.10 0.73 ± 0.07 1.02 ± 0.03 
  Post I-R 3.99 ± 0.30 3.33 ± 0.54 0.73 ± 0.30 0.82 ± 0.42 0.8 ± 0.05 1.01 ± 0.15 
 
 
Table 1.  Cardiovascular Function: Doppler Echocardiography results.  Left ventricular 
contractile function: left ventricular end-diastolic diameter (LVEDD), left ventricular end-
systolic diameter (LVESD), anterior wall diastolic thickness (AWDT), anterior wall 
systolic thickness (AWST), posterior wall diastolic thickness (PWDT) and posterior wall 
systolic thickness (PWST).  
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    FS (%) EF (%) HR (BPM) 
Sham         
  Baseline 37.57 ± 2.95 67.92 ± 3.80 309 ± 74.6 
  Post I-R 33.74 ± 7.49 62.43 ± 9.33 425 ± 56.3 
DMSO         
  Baseline 28.54 ± 4.95 54.88 ± 7.69 326 ± 85.9 
  Post I-R 17.04 ± 8.1 34.98 ± 14.34 344 ± 4.35 
Saline         
  Baseline 35.42 ± 11.84 64.25 ± 15.61 267 ± 17.8 
  Post I-R 24.51 ± 3.25 49.07 ± 5.35 313 ± 81.0 
RSV         
  Baseline 26.99 ±9.31 52.94 ± 15.47 340 ± 64.7 
  Post I-R 29.97 ± 7.24 57.61 ± 11.1 434 ± 63.5 
SIL         
  Baseline 42.87 ± 9.96 73.65 ± 10.28 297 ± 36.1 
  Post I-R 25.95 ± 2.63 51.82 ± 4.24 361 ± 77.0 
Saline + Sirtinol         
  Baseline 36.68 ± 7.79 66.40 ± 10.79 258 ± 43.9 
  Post I-R 31.17 ± 7.39 59.13 ± 10.41 384 ± 49.5 
RSV + Sirtinol         
  Baseline 32.94 ± 2.41 62.02 ± 3.70 388 ± 48.3 
  Post I-R 19.01 ± 2.74 39.54 ± 5.09 415 ± 27.2 
SIL + Sirtinol         
  Baseline 29.77 ± 2.20 57.13 ± 3.30 222 ± 7.57 
  Post I-R 19.13 ± 7.30 39.21 ± 13.03 334 ± 23.1 
 
Table 2.  Cardiovascular Function: Doppler Echocardiography results.  Left ventricular 
contractile function: fractional shortening (FS), heart rate (HR), and ejection fraction (EF). 
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3.6 Western Blot analysis of SIRT1, eNOS, iNOS, HSF1, HSP70, and PGC-1α 
To investigate the effect of SIL on the expression of signaling molecules involved 
in the upregulation of SIRT1, western blot analysis was performed as described in 
materials and methods: 2.10 Western blot analysis for SIRT1, HSP70, HSF1, eNOS, 
iNOS, and PGC-1α.  The results shown in Figure 10 show a significant increase in SIRT1 
expression, eNOS expression, and HSP70 expression (P<0.05) in homogenized adult ICR 
mice treated with 0.7 mg of SIL 24 hours prior to harvesting the mouse heart as described 
in materials and methods: 2.7 Healthy Heart Harvestation, Experimental Protocol 3.  
Further studies were performed to investigate the effect of SIL on the expression of iNOS, 
PGC-1α, and HSP70 following I-R injury as described in materials and methods: 2.4 
Myocardial Infarction Protocol, Experimental Protocol 2 (See Figure 2).  The results are 
shown in Figure 11 show a significant increase in iNOS expression and PGC-1α 
expression (P<0.05) compared to the Saline controls.  HSP70 expression following the 
administration of SIL and I-R injury also showed an increase in HSP70 expression 
however the results were not statistically significant (P>0.05).   
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Figure 10.  Cardiac expression of eNOS, SIRT1, and HSP70 in mice administered SIL 
(0.7 mg/kg), RSV (5 mg/kg), or Saline (volume matched 0.2ml) ip and sacrificed 24 h later 
for heart harvestation without I-R.  Top:  Representative western blots showing eNOS, 
SIRT1, and HSP70 protein expression.  Bottom:  Densitometric quantification of western 
blots normalized against the actin level for each sample.  n = 3/Group, * = P<0.05 vs. 
Saline. 
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24 hour pre-treatment, 30 minutes Ischemia, 24 hours Reperfusion 
 
 
 
 
 
 
Figure 11.  Cardiac expression of iNOS, PGC-1α, and HSP70 in mice treated with SIL 
(0.7 mg/kg), RSV (5 mg/kg), or Saline (volume matched 0.2ml) ip and 24 h later were 
subjected to 30 minutes of ischemia and 24 h of reperfusion before heart harvestation.  
Top:  Representative western blots showing iNOS, PGC-1α, and HSP70 protein 
expression.  Bottom:  Densitometric quantification of western blots normalized against the 
actin level for each sample.  n = 3/Group, * = P<0.05 vs. Saline 
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DISCUSSION 
 
 
 
 
4.1 R ationale of the Present study 
 The concept of using Sildenafil as a pharmacological preconditioning agent has 
been shown previously in our lab.6, 16  Resveratrol, a putative activator of SIRT1 has also 
been demonstrated to be a pharmacological preconditioning agent.14-16, 25  The cellular and 
molecular mechanisms mediating the cardioprotective mechanisms of SIRT1 have not 
been elucidated, and the aim of this study was to determine if SIRT1 acts as a mediator in 
the cardioprotective pathway of SIL following I-R injury.  SIRT1 has been shown to 
modulate common factors involved in the cardioprotective pathway of SIL, such as eNOS, 
iNOS, HSP70, and HSF1.14, 43, 47  Based on these studies, we postulated that SIL treatment 
ip would increase SIRT1 activity and expression.  To test this hypothesis a murine model 
was used in which healthy hearts, hearts following I-R injury, and cardiac myocytes were 
analyzed.  The effects of SIL were compared to the positive control RSV, the negative 
control Saline, and administration with Sirtinol, an inhibitor of SIRT1.  It was also 
hypothesized that SIL treatment would increase common factors involved in the 
cardioprotective pathway of SIRT1, and this hypothesis was tested using western blot 
analysis.  Another goal of this study was to determine if SIRT1 had an effect on the 
cardioprotective effect of SIL following I-R injury.  This hypothesis was tested by 
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analyzing infarct size in pre-treated murine heart samples following I-R and comparing 
baseline and post I-R function with Doppler echocardiography.   
 
4.2 SIRT1 is a key factor involved in the cardioprotective mechanism of Sildenafil 
following I-R injury 
 
 In the present study, Sirtinol blocked the infarct-limiting effects of SIL when 
administered to mice 30 minutes prior to ischemia.  Since Sirtinol is a putative inhibitor of 
SIRT124, this suggests that SIRT1 is involved in mediating SIL-induced cardioprotective 
signaling following I-R injury.  
 
4.3 Sildenafil increases SIRT1 activity in vivo and in vitro 
 The direct effect of SIL on SIRT1 was investigated by measuring SIRT1 activity in 
vivo and in vitro.  In in vivo studies, SIRT1 activity was increased in healthy ICR mice 
heart homogenates, as well as ICR mice hearts that had undergone I-R injury.  This 
indicates that SIL is either an upstream activator or direct activator of SIRT1.  To further 
investigate the effect of SIL on SIRT1 activity, in vitro studies were performed in adult 
ICR mice myocytes, where 1µM SIL was applied directly on the plated myocytes and 
incubated under 37 °C and 5% CO2, for 1 h.  As shown in Figure 9, SIRT1 activity was 
increased 450% compared to the control.  This also suggests that SIL is an activator of 
SIRT1.   
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4.4 Cardiac Function Studies 
In the previous studies, our laboratory has shown that Sildenafil improves cardiac 
function following I-R injury.  We have shown significantly less LVEDD and LVESD, 
improved FS, and less AWST and AWDT in SIL-treated mice vs. Saline controls after 
permanent occlusion of coronary artery.3  We contemplated that the Sirtinol would 
abrogate the cardioprotective effects of SIL by worsening of cardiac function following I-R 
injury.    However, the results from our studies were inconclusive because we assessed 
cardiac function 24h after reperfusion in limited number of mice.   
 
4.5 Sildenafil increased expression of common factors modulated by SIRT1 
 To further investigate the cardioprotective pathway of SIL, we assessed the 
expression of  SIRT1, eNOS, iNOS, HSF1, HSP70, and PGC-1α following treatment with 
SIL.  Our previous studies have established that SIL induces cardioprotective effects 
through NO generated from eNOS and iNOS and the opening of mitoKATP channels.6, 9, 18  
Moreover, we have demonstrated a  significant increase in eNOS and iNOS proteins 24 h 
post-MI after treatment with SIL vs. Saline.3  In the present study also, we observed an 
increase in eNOS and iNOS proteins 24 hours post I-R injury after treatment with SIL.  
SIRT1 has also been shown to upregulate eNOS expression and increase endothelium 
relaxation.47    NO has a role in preserving cardiomyocytes through opening mitoKATP 
channels, preventing Ca2+ overload3, and attenuating the formation of ROS.10  ROS are 
involved in many cardiovascular diseases such as I-R injury, congestive heart failure, and 
coronary heart disease.23, 24   Mitochondria are the main energy sources of cells, and 
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compromised mitochondrial function can lead to cardiovascular and metabolic diseases.25   
PGC-1α controls mitochondrial biogenesis and function, it plays an important role in cell 
survival during I-R.  RSV is believed to exert pharmacological preconditioning by 
activating PGC-1α through diverse upstream signaling pathways involving SIRT1 and 
NO.14  PGC-1α has been shown to be required for the adaptation to the stress-induced 
change in mitochondrial membrane potential.34  In this study, we observed an increase in 
PGC-1α expression in SIL-treated mice suggesting its potential role in preservation of 
mitochondrial membrane potential as demonstrated previously from our laboratory.46    
Heat Shock proteins, such as HSP70, play an important role in maintaining cellular 
homeostasis and aid in cardioprotection against I-R injury.  HSF1 is a gene that encodes a 
transcription factor that regulates gene expression in response to cellular stress, including 
the human HSP70 gene.  Both HSP70 and HSF1 have been shown to be upregulated 24 h 
following ischemic preconditioning.13  SIRT1 has been shown to regulate several 
transcription factors including HSF1 involved in the cellular stress response.  Activation of 
SIRT1  prolongs HSF1 binding to the heat shock promoter of HSP70 which may ensure 
sustain synthesis of this protein.43  In the present study, an increase in HSP70 expression in 
the heart was observed 24 hours in the post-ischemic and non-ischemic hearts after SIL 
administration.        
  
4.6 Study Limitations  
 SIRT1 deficient mice were not used in this study because they rarely survive 
postnatally and usually exhibit heart abnormalities.35  We realize the potential non-specific 
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effects of SIRT1 inhibitor, sirtinol.   Due to time constraints, transgenic mice 
overexpressing SIRT1 in heart muscle or siRNA studies could not be conducted.  We also 
could not consider the potential role of other Sirtuins such as SIRT2 in the cytosol and 
SIRT3 in the mitochondria that might be expressed in the myocytes and may possibly be 
involved in the cardioprotective pathway of SIL.   
 
4.7 Future Directions 
More thorough investigations should be conducted to elucidate the role of SIRT1 in 
SIL induced cardioprotection against I-R injury.  The 24 h time frame of reperfusion was 
selected to mimic the second window of ischemic preconditioning, allowing for 
transcriptional changes to occur and to effect protein expression.  Future studies can be 
done at different reperfusion time-points to determine the mechanism of cardioprotection 
of SIL through the activation of SIRT1.  The regulatory mechanisms that control SIRT1 
activity need to be elucidated for the appropriate use of pharmacological agents such as 
SIL in treatment of various disease processes.  Some studies have shown that the extent of 
SIRT1 expression also affects disease processes. Lower levels of SIRT1 expression have 
shown protective mechanisms, and greater levels of SIRT1 expression have contributed to 
the progression of disease processes.35, 36  The therapeutic potential of SIRT1 needs to be 
carefully evaluated at various dosages.    
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4.6 Clinical implications 
SIRT1 has been shown to protect against cardiovascular diseases, cancer, and 
neurodysfunctions.32   Pharmacological interventions to regulate SIRT1 activity have been 
successful in the past, and it is conceivable that in the near future more selective and 
powerful drugs can be used for therapeutic interventions in human disorders.32   In the 
present study, we have demonstrated that SIL exerts pharmalogical preconditioning by 
activating SIRT1 and increasing SIRT1 expression, and indicates that SIL may have 
additional therapeutic benefits through the activation of SIRT1.   
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